• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neurology, Other  • Oncology  • Brain Cancer  • Radiologic Imaging  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Alexandra Benouaich-Amiel, MD; Vincent Lubrano, MD; Mathieu Tafani, MD; Emmanuelle Uro-coste, MD, PhD; Pierre Gantet, PhD; Jean Christophe Sol, MD, PhD; Franck Roux, MD, PhD; Philippe Bousquet, MD; Anne Julian, MD; Jean Sabatier, MD, PhD; Michel Tremoulet, MD; Valerie Cances-Lauwers, MD; Marie Bernadette Delisle, MD, PhD; Michel Clanet, MD, PhD; Jean Philippe Esquerré, MD, PhD; Pierre Payoux, MD, PhD

Arch Neurol. 2010;67(3):370-372.

Objective  To assess the feasibility of synthesis of O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine (FET), a new positron emission tomographic (PET) tracer described in several studies but not yet considered standard in management of glioma, in routine practice and to determine FET uptake in a homogeneous group of patients with suspected high-grade glioma.

Design  Prospective nonrandomized trial.

Patients  Twelve patients with suspicion of high-grade glioma.

Results  The mean (SD) FET uptake ratio was 3.15 (0.72) for the 12 patients and 3.16 (0.75) for the 11 patients with glioblastoma.

Conclusion  The initial results are promising and indicate that FET PET is a valuable and applicable tool for the imaging of high-grade glioma.

Author Affiliations: Pole NeuroSciences, Central Hospitalo Universitaire (CHU) Toulouse (Drs Benouaich-Amiel, Lubrano, Sol, Roux, Bousquet, Sabatier, Tremoulet, and Clanet); National Institute of Health and Medical Research (INSERM) U 825, Toulouse (Drs Lubrano, Roux, and Payoux); Research Team (EA) 3033, Université Paul Sabatier, Toulouse (Drs Tafani, Gantet, Julian, and Esquerré); and Pole Pharmacie (Dr Tafani), Pole Biologie (Drs Uro-coste and Delisle), Pole Imagerie (Drs Julian, Esquerré, and Payoux), Pole Santé-Société Réadaptation, CHU Toulouse (Dr Cances-Lauwers), France.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis
Dunet et al.
JNM 2012;53:207-214.
ABSTRACT | FULL TEXT